Key facts
- This page summarizes Alfred Sandrock's Form 4 filing for BIOGEN INC. (BIIB).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 09 Jun 2021, 19:05.
Alfred Sandrock - 07 Jun 2021 Form 4 Insider Report for BIOGEN INC. (BIIB)
- Reporting relationship
- Head of Research & Development
- Issuer ticker
- BIIB
- Reported as of
- 07 Jun 2021
- Net transaction value
- -$3,375,680
- SEC form
- 4
- Accepted by SEC
- 09 Jun 2021, 19:05:57 UTC
- Next SEC filing
- 09 Feb 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Suzanne Murray, Attorney in Fact for Alfred W. Sandrock, Jr.
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Alfred Sandrock filed Form 4 for BIOGEN INC. (BIIB) on 09 Jun 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: -$3,375,680.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BIIB
transaction
Common Stock
Sale
- Transaction value
- $3,375,680
- Shares
- -7,672
- Change %
- -43%
- Price
- $440.00
- Shares after
- 10,169
- Date
- 07 Jun 2021
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934.
Footnote F2
Includes 102.902 shares acquired under the Biogen Inc. employee stock purchase plan on 3/31/2021.